Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia.
Journal: Transplantation and cellular therapy
Published: April 21, 2026
Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene.
Journal: Blood
Published: September 19, 2025
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.
Journal: Bone marrow transplantation
Published: April 21, 2025
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement.
Journal: Blood advances
Published: January 02, 2025
Advancements in targeted therapies for acute myeloid leukemia.
Journal: Current opinion in pharmacology
Published: October 24, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 17, 2024
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia.
Journal: Haematologica
Published: February 12, 2024
Last Updated: 09/26/2026